Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
about
New Therapeutic Concept of NAD Redox Balance for Cisplatin NephrotoxicityMechanisms of Cisplatin nephrotoxicityPlant-Derived Agents for Counteracting Cisplatin-Induced NephrotoxicityRenal insufficiency and cancer treatmentsOxaliplatin-induced acute renal failure presenting clinically as thrombotic microangiopathy: think of acute tubular necrosis.Salt suppresses IFNγ inducible chemokines through the IFNγ-JAK1-STAT1 signaling pathway in proximal tubular cellsPulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer.Silymarin selectively protects human renal cells from cisplatin-induced cell death.Pathophysiology of cisplatin-induced acute kidney injury.Multiple analytical approaches demonstrate a complex relationship of genetic and nongenetic factors with cisplatin- and carboplatin-induced nephrotoxicity in lung cancer patientsPostoperative myocardial injury after major head and neck cancer surgery.Drug-induced impairment of renal function.Pharmacokinetics and disposition of a localized lymphatic polymeric hyaluronan conjugate of cisplatin in rodents.Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patientsInhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancerPharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal functionTherapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injuryLower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.Anaesthetic Considerations in the Perioperative Management of Cytoreductive Surgery and Hyperthermic Intraperitoneal ChemotherapyHyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.Bridging translation for acute kidney injury with better preclinical modeling of human diseaseIncreasing cGMP-dependent protein kinase I activity attenuates cisplatin-induced kidney injury through protection of mitochondria functionPromising particle-based vaccines in cancer therapy.Role of CFTR in oxidative stress and suicidal death of renal cells during cisplatin-induced nephrotoxicity.Klotho has dual protective effects on cisplatin-induced acute kidney injury.Use of high-dose cisplatin with aprepitant in an outpatient setting.Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update.Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study.The ability of mannitol to decrease cisplatin-induced nephrotoxicity in children: real or not?Clinical relevance of autophagic therapy in cancer: Investigating the current trends, challenges, and future prospects.DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8.Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer.Reducing excessive toxicity in ovarian cancer treatment: a personalized approach.Total Coumarins from Hydrangea paniculata Protect against Cisplatin-Induced Acute Kidney Damage in Mice by Suppressing Renal Inflammation and Apoptosis.Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage?Risk Factors for Nephrotoxicity Associated with Cisplatin.Ameliorative effect of lycopene effect on cisplatin-induced nephropathy in patient.Effect of curcumin on cisplatin- and oxaliplatin-induced oxidative stress in human embryonic kidney (HEK) 293 cells.
P2860
Q26765483-22F2BEEC-81ED-43BE-B60D-9D20E95DFCABQ26996320-244FE4EE-518D-42B0-B053-7B1E93FC2C1DQ28070295-29C2A783-FBBE-4153-8159-360D65859940Q28079168-4B5C020C-05A9-4D92-8B8D-34916638DBB0Q33422905-CDD44C74-B9D2-400E-8AEE-A8B224A68B78Q33582779-A22D1BDD-5FC3-49AC-9010-37335CFA916DQ33862921-812DF4E3-98B4-46D4-B68D-32785696246EQ33904503-90282452-19E6-42E2-BE16-74A076DCE93AQ34073302-BEDC6365-5B58-4E6F-B3D7-2EFAF242E1F3Q34177673-78BAA63F-CEC6-49A7-A310-BBAFE6EEB1EAQ34474312-353C06B9-7E1E-45FC-A971-2A7C4FA213ADQ34731462-2CE2B1BD-D8EF-487C-9AE8-F00C4517F2E4Q35009186-DE386774-75C4-4196-817A-79462078F371Q35185118-F54EE593-07AF-4FA9-B60C-73C99F9672FFQ35572426-60A21B83-EAF5-4559-A5AC-90DBFD2ED2E7Q35972223-24DF5DE3-BBAA-4D51-9B4B-A1C0E02A8662Q36111191-6D344F13-A606-451B-B5A5-B6222BA9615DQ36208901-D710ECB0-E415-4F36-BC61-9B9DD4359A1CQ36285665-B7D2B345-6695-4F26-93F8-F7855314869AQ36445285-0FA073E0-E0B1-42CA-BC94-BE9B18BE731AQ36758897-626BB6F9-C9AA-4C6D-A462-C3FEAE71684DQ36948510-9F10F478-CF26-49E3-9662-CF997B8F1F0CQ36957116-11A79432-1ED9-42A7-805A-87AEC8AB6040Q37142629-5CB2103C-5217-4E7E-8659-AD28380A9643Q37259642-0DF40764-8381-4A2F-9041-64F7F56D75ABQ37299627-144DCB49-4B05-4066-8AC3-D526356A9D99Q37678608-10373013-36AB-4C8F-B95D-41C21744A915Q37924902-25CC8563-CBD3-4BC7-99AB-BA482F0423A6Q37989844-DD12ACD6-0210-44E7-B82A-D23AE9475973Q38622569-5F0D579B-92EB-4795-9027-C651A74C1286Q38641130-FE2713FE-9E41-462B-8FC7-D6812E02FAF4Q38689955-8F16CC7F-C189-4D0F-B33C-84D40FAAD2EDQ38697324-A363D1A4-1038-4629-B825-343BDC6F35B6Q38786021-4A571710-B0D8-457D-9450-A819565EEE94Q39739012-F1ED495E-4A3E-4A29-894C-B5A8FBCCA034Q41991953-6AE02C90-50EA-498E-AB94-2C404CFBED29Q42228963-09885C8F-199D-479D-99FA-F3E4D216A7E0Q42290357-3B3A4F78-A10B-44ED-8C1D-86EEBE4E635DQ42361921-E8E74226-E75A-49A8-B389-F8E663A100EFQ42740245-6E5CC576-09F5-461A-8D29-A89290D00B72
P2860
Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Prevention of cisplatin nephro ...... Interest Group on Cancer Care.
@ast
Prevention of cisplatin nephro ...... Interest Group on Cancer Care.
@en
Prevention of cisplatin nephro ...... Interest Group on Cancer Care.
@nl
type
label
Prevention of cisplatin nephro ...... Interest Group on Cancer Care.
@ast
Prevention of cisplatin nephro ...... Interest Group on Cancer Care.
@en
Prevention of cisplatin nephro ...... Interest Group on Cancer Care.
@nl
prefLabel
Prevention of cisplatin nephro ...... Interest Group on Cancer Care.
@ast
Prevention of cisplatin nephro ...... Interest Group on Cancer Care.
@en
Prevention of cisplatin nephro ...... Interest Group on Cancer Care.
@nl
P2093
P2860
P1476
Prevention of cisplatin nephro ...... Interest Group on Cancer Care.
@en
P2093
Corinne Isnard-Bagnis
European Society of Clinical Pharmacy Special Interest Group on Cancer Care
Gilbert Deray
Jean-Baptiste Rey
P2860
P2888
P304
P356
10.1007/S00280-008-0711-0
P577
2008-03-04T00:00:00Z
P5875
P6179
1033938765